In a study of 22 osteosarcomas by our lab, mRNA overexpression of RUNX2 was on average 3.3 times higher in tumours that had responded poorly (<90% necrosis) to neoadjuvant chemotherapy relative to tumours with good response (>90% necrosis). This evidence concerns the gene RUNX2 and neoplasm.